MCID: SFT003
MIFTS: 56

Soft Tissue Sarcoma malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Soft Tissue Sarcoma

About this section

Aliases & Descriptions for Soft Tissue Sarcoma:

Name: Soft Tissue Sarcoma 48 27 38
 
Sarcoma 68

Classifications:



Summaries for Soft Tissue Sarcoma

About this section
NIH Rare Diseases:48 Soft tissue sarcoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of the soft tissues of the body. These tissues connect, support and surround other body parts and may include muscle, fat, blood vessels, lymph vessels, nerves, tendons and the lining of joints. Many people with early soft tissue sarcoma have no signs or symptoms of the condition. When present, symptoms depend on the location and size of the tumor but may include a palpable lump under the skin, pain, or difficulty breathing. Most cases occur sporadically in people with little to no family history of the condition. People who have previously received radiation therapy and those with certain inherited disorders (such as Gorlin syndrome, Gardner syndrome, Li-Fraumeni syndrome, Tuberous sclerosis, neurofibromatosis type 1, and Werner syndrome) have an increased risk of developing a soft tissue sarcoma. The best treatment options depend on many factors but may include surgery, chemotherapy, and radiation therapy. Last updated: 10/17/2016

MalaCards based summary: Soft Tissue Sarcoma, also known as sarcoma, is related to gastrointestinal stromal tumor and plasmacytoma. An important gene associated with Soft Tissue Sarcoma is TP53 (Tumor Protein P53), and among its related pathways are Inhibition of Ribosome Biogenesis by p14(ARF) and PDGFR-alpha signaling pathway. The drugs thiotepa and ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related mouse phenotypes are adipose tissue and respiratory system.

MedlinePlus:38 Your soft tissues connect, support, or surround other tissues. examples include your muscles, tendons, fat, and blood vessels. soft tissue sarcoma is a cancer of these soft tissues. there are many kinds, based on the type of tissue they started in. they may cause a lump or swelling in the soft tissue. sometimes they spread and can press on nerves and organs, causing problems such as pain or trouble breathing. no one knows exactly what causes these cancers. they are not common, but you have a higher risk if you have been exposed to certain chemicals, have had radiation therapy, or have certain genetic diseases. doctors diagnose soft tissue sarcomas with a biopsy. treatments include surgery to remove the tumor, radiation therapy, chemotherapy, or a combination. nih: national cancer institute

Wikipedia:71 A soft-tissue sarcoma is a form of sarcoma that develops in connective tissue, though the term is... more...

Related Diseases for Soft Tissue Sarcoma

About this section

Diseases related to Soft Tissue Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 238)
idRelated DiseaseScoreTop Affiliating Genes
1gastrointestinal stromal tumor31.4EGFR, MKI67, TP53, VEGFA
2plasmacytoma29.4EGFR, TP53, VEGFA
3renal cell carcinoma27.8ABCB1, EGFR, IFNG, PIK3CA, VEGFA
4breast cancer26.5ABCB1, BCL2, EGFR, MDM2, MKI67, PIK3CA
5lung cancer26.1ABCB1, BCL2, EGFR, MDM2, PIK3CA, TERT
6colorectal cancer25.2ABCB1, BCL2, EGFR, IFNG, MDM2, PIK3CA
7soft tissue sarcoma childhood12.1
8alveolar soft-part sarcoma11.8
9dermatofibrosarcoma protuberans11.4
10epithelioid sarcoma11.4
11rhabdomyosarcoma11.3
12myxoid liposarcoma11.2
13embryonal rhabdomyosarcoma11.2
14li-fraumeni syndrome11.2
15sarcoma, synovial11.2
16sarcoma11.1
17hemangiopericytoma, malignant11.0
18rhabdomyosarcoma 2, alveolar10.9
19rhabdomyosarcoma, somatic10.9
20rhabdomyosarcoma, embryonal, 210.9
21synovium cancer10.9
22muscle cancer10.9
23heart malignant hemangiopericytoma10.9
24follicular dendritic cell sarcoma10.9
25undifferentiated pleomorphic sarcoma10.9
26chromosome 7p duplication10.7MDM2, TP53
27pasli disease10.6MDM2, TP53
28median neuropathy10.6MDM2, TP53
29ampulla of vater squamous cell carcinoma10.6MDM2, TP53
30multiple carboxylase deficiency10.6MDM2, TP53
31split hand split foot malformation autosomal recessive10.6MKI67, TP53
32prostate calculus10.5MDM2, TP53
33panner disease10.5IFNG, TNF
34baetz-greenwalt syndrome10.5IFNG, TNF
35oral pharyngeal disorders10.5MKI67, TP53
36autoimmune pancreatitis10.5IFNG, TNF
37keratopathy10.5IFNG, TP53
38cutaneous leishmaniasis10.5TNF, VEGFA
39graft-versus-host disease, protection against10.5IFNG, TNF
40pseudoangiomatous stromal hyperplasia10.5PIK3CA, TP53
41pulmonary hypertension10.4BCL2, TNF
42primary systemic mycosis10.4IFNG, TNF
43duodenum cancer10.4TNF, TP53
44emerinopathy10.4MDM2, MKI67, TP53
45mixed extragonadal germ cell cancer10.4MDM2, MKI67, TP53
46pancreatitis, pediatric10.4MKI67, PIK3CA
47gonococcal synovitis10.3IFNG, TNF
48uterine body mixed cancer10.3BCL2, TP53
49adult teratoma10.3BCL2, TP53
50vaginal yolk sac tumor10.3MDM2, TP53

Graphical network of the top 20 diseases related to Soft Tissue Sarcoma:



Diseases related to soft tissue sarcoma

Symptoms & Phenotypes for Soft Tissue Sarcoma

About this section

MGI Mouse Phenotypes related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

41 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053758.2BCL2, EGFR, PIK3CA, TNF, TP53
2MP:00053888.1BCL2, EGFR, IFNG, TNF, TP53, VEGFA
3MP:00053808.0EGFR, IFNG, MDM2, PIK3CA, TNF, TP53
4MP:00053917.7BCL2, EGFR, IFNG, PIK3CA, TNF, TP53
5MP:00053827.6BCL2, EGFR, IFNG, MDM2, TNF, TP53
6MP:00053867.5ABCB1, BCL2, IFNG, MDM2, PIK3CA, TNF
7MP:00053697.5BCL2, EGFR, IFNG, MDM2, PIK3CA, TNF
8MP:00053707.4ABCB1, EGFR, IFNG, LATS1, MDM2, TNF
9MP:00053677.4BCL2, EGFR, IFNG, MDM2, TP53, VEGFA
10MP:00053907.3EGFR, IFNG, MDM2, PIK3CA, TERT, TNF
11MP:00028737.2EGFR, IFNG, LATS1, MDM2, MKI67, TERT
12MP:00030127.1ABCB1, EGFR, IFNG, LATS1, MDM2, PIK3CA
13MP:00107717.1BCL2, EGFR, IFNG, LATS1, MDM2, PIK3CA
14MP:00020066.5BCL2, EGFR, IFNG, LATS1, MDM2, PIK3CA
15MP:00053846.5BCL2, EGFR, IFNG, LATS1, MDM2, PIK3CA
16MP:00053976.4ABCB1, BCL2, EGFR, IFNG, MDM2, TERT
17MP:00053856.2ABCB1, BCL2, EGFR, IFNG, LATS1, MDM2
18MP:00053876.2ABCB1, BCL2, EGFR, IFNG, MDM2, PIK3CA
19MP:00053816.1ABCB1, BCL2, EGFR, IFNG, MDM2, TERT
20MP:00053796.0ABCB1, BCL2, EGFR, IFNG, LATS1, MDM2
21MP:00053896.0ABCB1, BCL2, EGFR, IFNG, LATS1, MDM2
22MP:00107685.8ABCB1, BCL2, EGFR, IFNG, LATS1, MDM2
23MP:00053785.8ABCB1, BCL2, EGFR, IFNG, LATS1, MDM2
24MP:00036315.7ABCB1, BCL2, EGFR, IFNG, LATS1, MDM2
25MP:00053765.7ABCB1, BCL2, EGFR, IFNG, LATS1, MDM2

Drugs & Therapeutics for Soft Tissue Sarcoma

About this section

Drugs for Soft Tissue Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 596)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
BleomycinapprovedPhase 4, Phase 3, Phase 2, Phase 115311056-06-75360373
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
BLM
Blenoxane
Bleo
Bleocin
Bleogin
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
Bleomycin A(2)
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin B(2)
Bleomycin B2
Bleomycin sulfate
Bleomycin sulphate
 
Bleomycine
Bleomycine [INN-French]
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
LMPK14000006
LS-44860
LS-524
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
bleomycin
bleomycin a2
2
Doxorubicinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1171423214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
3
Efavirenzapproved, investigationalPhase 4, Phase 3405154598-52-464139
Synonyms:
(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(-)-Efavirenz
(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben
(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
154598-52-4
1ikv
1ikw
2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9
6-chloro-4-(2-Cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
AC-19049
AC1L20IX
BIDD:GT0383
C08088
C14H9ClF3NO2
CHEBI:119486
CHEMBL223228
CID64139
CPD000466351
D00896
DB00625
DB07709
DMP 266
DMP-266
EFV
 
EFZ
Efavirenz
Efavirenz (JAN/INN)
Efavirenzum
Eravirenz
HMS2051J08
HMS2090N16
HSDB 7163
L 743726
L-741211
L-743,726
L-743725
L-743726
LS-173464
MLS000759465
MLS001424087
Met-SDF-1.beta. & Efavirenz
Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz
MolPort-003-983-924
NSC742403
SAM001246667
SBB066062
SMR000466351
Stocrin
Strocin (TM)
Sustiva
Sustiva (TM)
Sustiva (TN)
UNII-JE6H2O27P8
ZINC02020233
efavirenz
efavirenz, (S)-isomer
zoxazin-2-one
Éfavirenz
4
Vincristineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 19042068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
5
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
6
Ritonavirapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1870155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
7
Oxaliplatinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1141261825-94-35310940, 9887054, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
8
Bevacizumabapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 11968216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
9
NevirapineapprovedPhase 4, Phase 3222129618-40-24463
Synonyms:
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody)
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
129618-40-2
1vrt
2hny
AC-643
AC1L1I81
BI RG 587
BI-RG-587
BI-RG-587 & CD4-IgG
BIDD:GT0326
BIRG 0587
BIRG 587
BIRG-0587
BIRG-587
BIRG587
Bio-0789
C07263
C15H14N4O
CHEBI:44659
CHEMBL57
CID4463
CPD000048458
Cahill May Roberts Brand of Nevirapine
D00435
D019829
DB00238
DB08311
 
HMS2051J09
HSDB 7164
I02-0310
LS-2289
MLS000084585
MLS000759409
MLS001055309
MLS001201730
MolPort-002-507-817
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin
NCGC00065890-02
NEV
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
NSC 641530
NSC641530
NVP
Nevirapine
Nevirapine & CD4-IgG
Nevirapine & PRO 140
Nevirapine (JAN/USP/INN)
Nevirapine [USAN:INN]
Promeco Brand of Nevirapine
S1742_Selleck
SAM001246551
SMR000048458
STK580320
UNII-99DK7FVK1H
Viramune
Viramune (TN)
Viramune(TM)
Viramune, BI-RG 587, Nevirapine
ZINC00004778
nevirapine
10
Lamivudineapproved, investigationalPhase 4, Phase 2, Phase 3613134678-17-460825
Synonyms:
(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(+/-)-3TC
(+/-)-BCH-189
(+/-)-SddC
(-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-2'-Deoxy-3'-thiacytidine
(-)-BCH 189
(-)-BCH-189
(-)-SddC
(-)-beta-L-2',3'-Dideoxy-3'-thiacytidine
(-)NGPB-21
(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To
134678-17-4
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)
3'-Thia-2',3'-dideoxycytidine
3TC
3TC & GNA
3TC & SST
3TC (AIDS INITIATIVE) (AIDS INITIATIVE)
3TC and NV-01
3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine
4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
480434-79-5
AC-1416
AC1L1TZZ
AC1Q6C34
BCH 189
BCH-189
BCH-790
BCH189
BIDD:GT0033
Bio-0652
C07065
C8H11N3O3S
CCRIS 9274
CHEBI:133986
CHEMBL141
CID60825
CPD000466319
D00353
D019259
 
DB00709
DRG-0126
DTHC
Epivir
Epivir (TN)
Epivir(TM)
Epivir-HBV
Epzicom
FT-0082667
GG-714
GR 109714X
GR-109714X
GR109714X
HHA & 3TC
HHA & Lamivudine
HMS2051D21
HSDB 7155
Hepitec
Heptivir
Heptodin
Heptovir
L0217
LMV
LS-2107
Lamivir
Lamivudin
Lamivudina
Lamivudine
Lamivudine & GNA
Lamivudine (JAN/USP/INN)
Lamivudine [USAN:BAN:INN]
Lamivudine [USAN:INN:BAN]
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-Isomer
Lamivudinum
MLS000759424
MLS001424097
MolPort-002-507-347
NCGC00159341-03
NCGC00159341-04
NSC620753
S1706_Selleck
SAM001246582
SAM002589994
SMR000466319
STK801940
UNII-2T8Q726O95
ZINC00012346
Zeffix
Zefix
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
lamivudine
11
Emtricitabineapproved, investigationalPhase 4, Phase 3439143491-57-060877
Synonyms:
(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-.beta.-L-FTC
(-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-2'-Deoxy-5-fluoro-3'-thiacytidine
(-)-FTC
(-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-cis-4-amino-5-Fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-amino-5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
.beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine
143491-54-7
143491-57-0
145213-48-5
2',3',5-FTC
2',3'-Dideoxy-5-fluoro-3'-thiacytidine
2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine
2'-Deoxy-5-fluoro-3'-thiacytidine
2-FTC
3'-Thia-2'.3'-dideoxy-5-fluorocytidine
4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
4-amino-5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine
524W91
AC1L1U3I
AC1Q4KUB
BW 1592
 
BW 524W91
BW-524W91
BW524W91
C122114
C12599
C8H10FN3O3S
CHEBI:31536
CHEMBL885
CID60877
Coviracil
Coviracil(TM)
D01199
DB00879
DRG-0208
Emtricitabin
Emtricitabina
Emtricitabine
Emtricitabine (JAN/USAN/INN)
Emtricitabinum
Emtriva
Emtriva (TN)
Emtriva(TM)
FT-0080009
HMS2089I05
HSDB 7337
LS-135838
LS-173184
NCGC00164564-01
RCV
Racivir
SBB066061
TL8000958
UNII-G70B4ETF4S
ZINC03629271
beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine
dOTFC
emtricitabine
12
LopinavirapprovedPhase 4, Phase 2, Phase 3342192725-17-092727
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
A 157378
A 157378.0
A-157378-0
A-157378.0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
AC1L3OPJ
AIDS032937
 
Aluviran
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Koletra
LPV
LS-173766
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
13
Tenofovirapproved, investigationalPhase 4, Phase 3733147127-20-6464205
Synonyms:
(R)-9-(2-Phosphonomethoxypropyl)adenine
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-9-(2-phosphonomethoxypropyl)adenine
(R)-PMPA
147127-20-6
206184-49-8
AC-760
AC1LA9BO
Anh. tenofovir
Anhydrous tenofovir
Apropovir
CHEBI:45809
CHEMBL483
CID464205
D,L-Tenofovir
DB00300
GNA & Tenofovir
GS 1275
GS 1278
GS1278
 
HHA & Tenofovir
KS-5021
MolPort-003-850-411
NCGC00167535-01
PMPA
PMPA-(R)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI)
Phosphonic acid, [[2-(6-amino-9H-purin-9
S1401_Selleck
TDF
TFV
Tenefovir
Tenofovir
Tenofovir (anh.)
Tenofovir disoproxil
Tenofovir disoproxil fumarate
UNII-99YXE507IL
Viread
Viread, Tenofovir
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
14
Capecitabineapproved, investigationalPhase 4, Phase 2, Phase 11296154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
15
Stavudineapproved, investigationalPhase 41723056-17-518283
Synonyms:
1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2
132425-31-1
2',3' Didehydro 3' deoxythymidine
2',3'-Anhydrothymidine
2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI)
2',3'-Didehydro-2',3'-dideoxythmidine
2',3'-Didehydro-3'-deoxythimidine
2',3'-Didehydro-3'-deoxythymidine
3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor
3'-Deoxy-2',3'-didehydrothymidine
3'-Deoxy-2'-thymidinene
3056-17-5
AC-5263
AC1L2BQ9
AC1Q6BSH
BB_NC-1008
BIDD:GT0082
BMY 27857
BMY-27857
BMY27857
BRN 0618327
Bristol-Myers Brand of Stavudine
Bristol-Myers Squibb Brand of Stavudine
C07312
CHEBI:207119
CHEMBL991
CID18283
CPD000058350
CPD000673569
D 1413
D 4T
D 4T (nucleoside)
D00445
D018119
D1413_SIGMA
D3580
D4T & GM-CSF
D4TMBY-27857-3
DB00649
Dideoxydidehydrothymidine
EU-0100336
Estavudina
Estavudina [INN-Spanish]
FT-0082665
 
HMS2051O20
HSDB 7338
LS-1160
Lopac0_000336
MLS000028546
MLS000759504
MLS001055348
MLS001077292
MolPort-002-507-283
NCGC00023212-03
NCGC00023212-04
NCGC00023212-05
NCGC00023212-07
NCGC00023212-08
NCGC00023212-09
NCGC00023212-10
NSC 163661
NSC163661
SAM001246729
SAM002589948
SMR000058350
SMR000673569
STK801888
STV
Sanilvudine
Sanilvudine (JAN)
Stavudin
Stavudine
Stavudine (USAN/INN)
Stavudine [USAN:BAN:INN]
Stavudine [USAN:INN:BAN]
Stavudine [Usan:Ban:Inn]
Stavudine, Monosodium Salt
Stavudinum
Stavudinum [INN-Latin]
Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)- (7CI,8CI)
UNII-BO9LE4QFZF
ZINC00137884
Zent
Zerit
Zerit (TN)
Zerit XR
Zerit Xr
Zerit(TM)
Zerut XR
d4T
ddeThd
ddeTyd
sanilvudine
stavudine
16
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1171431703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
17
protease inhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 15320
Synonyms:
 
protease inhibitors
18Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112770
19HIV Protease InhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 15319
20Antiviral AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 19732
21Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110627
22Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14143
23Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
24Antineoplastic Agents, AlkylatingPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14474
25Antimetabolites, AntineoplasticPhase 4, Phase 2, Phase 3, Phase 17171
26Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14072
27Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 14945
28VaccinesPhase 4, Phase 1, Phase 26428
29Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121402
30Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14855
31AntimetabolitesPhase 4, Phase 2, Phase 3, Phase 111774
32Cytochrome P-450 CYP3A InducersPhase 4, Phase 3, Phase 2, Phase 11101
33Anti-Retroviral AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13232
34Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14694
35ImmunoglobulinsPhase 4, Phase 3, Phase 1, Phase 26045
36Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110884
37AntibodiesPhase 4, Phase 3, Phase 1, Phase 26045
38Antibodies, MonoclonalPhase 4, Phase 3, Phase 1, Phase 23795
39Anti-HIV AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13100
40Antidepressive AgentsPhase 42666
41Antimanic AgentsPhase 4, Phase 1, Phase 2790
42Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Phase 17793
43Tranquilizing AgentsPhase 4, Phase 2, Phase 14164
44Psychotropic DrugsPhase 4, Phase 2, Phase 16279
45Lithium carbonatePhase 4232554-13-2
46Central Nervous System DepressantsPhase 4, Phase 2, Phase 3, Phase 112806
47Cytochrome P-450 CYP3A InhibitorsPhase 4, Phase 2, Phase 31666
48Cytochrome P-450 CYP2C9 InhibitorsPhase 4, Phase 3658
49Cytochrome P-450 Enzyme InhibitorsPhase 4, Phase 2, Phase 33822
50Reverse Transcriptase InhibitorsPhase 4, Phase 2, Phase 3, Phase 11880

Interventional clinical trials:

(show top 50)    (show all 1543)
idNameStatusNCT IDPhase
1EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in ChildrenUnknown statusNCT00339118Phase 4
2Optimizing Influenza Vaccination in Surgical Oncology PatientsUnknown statusNCT01698177Phase 4
3HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXTCompletedNCT00380770Phase 4
4Anti-Retrovirals for Kaposi's SarcomaCompletedNCT00444379Phase 4
5OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.CompletedNCT00577031Phase 4
6Physical Characteristics of Retrieved Massive AllograftsCompletedNCT00160758Phase 4
7HLA Sensitization Following Major Cortical Allograft Bone ProceduresCompletedNCT00160719Phase 4
8Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal CancerRecruitingNCT02301962Phase 4
9Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat OsteosarcomaRecruitingNCT01669369Phase 4
10Stereotactic Body Radiotherapy for Head and Neck TumorsActive, not recruitingNCT01344356Phase 4
11Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue SarcomaUnknown statusNCT00334854Phase 3
12An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized TrialUnknown statusNCT00384735Phase 3
13The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine SarcomasUnknown statusNCT00162721Phase 3
14Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's SarcomaUnknown statusNCT00002516Phase 3
15Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue SarcomaUnknown statusNCT00346164Phase 3
16Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's SarcomaUnknown statusNCT00020566Phase 3
17A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's SarcomaUnknown statusNCT00002318Phase 3
18Combination Chemotherapy in Treating Young Patients With Nonmetastatic RhabdomyosarcomaUnknown statusNCT00379457Phase 3
19TB-IRIS NSAID Cox-2 Inhibitor Prevention TrialUnknown statusNCT02060006Phase 3
20Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic CancerUnknown statusNCT01087268Phase 3
21Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity CancerUnknown statusNCT00954174Phase 3
22Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal TumorUnknown statusNCT00685828Phase 3
23Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal TumorUnknown statusNCT00103168Phase 3
24A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced OsteosarcomaUnknown statusNCT02099396Phase 2, Phase 3
25Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade OsteosarcomaUnknown statusNCT00691236Phase 2, Phase 3
26A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue SarcomaCompletedNCT01440088Phase 3
27Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue SarcomaCompletedNCT00142571Phase 3
28Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior TherapyCompletedNCT00753688Phase 3
29Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue SarcomaCompletedNCT01168791Phase 3
30Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue SarcomaCompletedNCT01327885Phase 3
31Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00003212Phase 3
32Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00061984Phase 3
33Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue SarcomaCompletedNCT00003052Phase 3
34A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal SarcomaCompletedNCT00131898Phase 3
35Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or PelvisCompletedNCT00091351Phase 3
36A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue SarcomaCompletedNCT00001300Phase 3
37Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue SarcomaCompletedNCT00002641Phase 3
38Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue SarcomaCompletedNCT00002764Phase 3
39Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue SarcomaCompletedNCT00002898Phase 3
40Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal TumorCompletedNCT00006734Phase 3
41A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide ChemotherapiesCompletedNCT00699517Phase 3
42Doxorubicin in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002985Phase 3
43Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)CompletedNCT00538239Phase 3
44An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)CompletedNCT00796120Phase 3
45A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's SarcomaCompletedNCT00002319Phase 3
46Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.CompletedNCT00002147Phase 3
47Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's SarcomaCompletedNCT00003350Phase 3
48A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in ZimbabweCompletedNCT00834457Phase 2, Phase 3
49Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS PatientsCompletedNCT00002445Phase 3
50Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's SarcomaCompletedNCT00002105Phase 3

Search NIH Clinical Center for Soft Tissue Sarcoma

Inferred drug relations via UMLS68/NDF-RT46:

Genetic Tests for Soft Tissue Sarcoma

About this section

Genetic tests related to Soft Tissue Sarcoma:

id Genetic test Affiliating Genes
1 Soft Tissue Sarcoma27

Anatomical Context for Soft Tissue Sarcoma

About this section

MalaCards organs/tissues related to Soft Tissue Sarcoma:

36
Bone, Lung, T cells, Uterus, Brain, Kidney, Bone marrow

Publications for Soft Tissue Sarcoma

About this section

Articles related to Soft Tissue Sarcoma:

(show top 50)    (show all 992)
idTitleAuthorsYear
1
Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. (28068242)
2017
2
Treatment of soft tissue sarcoma: a focus on earlier stages. (27918202)
2017
3
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma. (28067691)
2017
4
The importance of treating by histological subtype in advanced soft tissue sarcoma. (27918201)
2017
5
Evolution in soft tissue sarcoma. (27918200)
2017
6
Surveillance Imaging Patterns and Outcomes Following Radiation Therapy and Radical Resection for Localized Extremity and Trunk Soft Tissue Sarcoma. (28058559)
2017
7
Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays. (28045549)
2017
8
Antia89proliferative activity of epigallocatechina893a89gallate and silibinin on soft tissue sarcoma cells. (27909727)
2017
9
Targeting angiogenesis in advanced soft tissue sarcoma: Tivozanib - hype or me-too? (27998962)
2016
10
Radiologic Response Assessment in Pediatric Soft Tissue Sarcoma: Computed-Assisted Volume Evaluation. (27939125)
2016
11
Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. (27908980)
2016
12
Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children's Oncology Group. (27642091)
2016
13
Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy. (27930525)
2016
14
Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma. (27561088)
2016
15
Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis. (27663525)
2016
16
Progress for Soft Tissue Sarcoma. (27997639)
2016
17
Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma. (27219337)
2016
18
Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis. (27189833)
2016
19
Prognosis value of Hypoxia-inducible factor-1I+ expression in patients with bone and soft tissue sarcoma: a meta-analysis. (27606158)
2016
20
Epigenetic re-expression of HIF-2I+ suppresses soft tissue sarcoma growth. (26837714)
2016
21
Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case report. (27073488)
2016
22
Extremity Soft Tissue Sarcoma: Tailoring Resection to Histologic Subtype. (27591492)
2016
23
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. (26897615)
2016
24
Chondroitin sulfate synthase 1 expression is associated with malignant potential of soft tissue sarcomas with myxoid substance. (26997434)
2016
25
Soft tissue sarcoma in the dog - part 1: a current review. (27624929)
2016
26
Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. (27566012)
2016
27
A pilot trial of doxorubicin containing phosphatidyldiglycerol based thermosensitive liposomes in spontaneous feline soft tissue sarcoma. (27592502)
2016
28
Patients with soft tissue sarcoma comprise a higher probability of comorbidities than cancer-free individuals. A secondary data analysis. (27957779)
2016
29
Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. (27069131)
2016
30
Prognostic Significance of Apoptosis-related Markers in Patients With Soft-Tissue Sarcomas of Extremities. (25906122)
2016
31
In brief: Two Drugs for soft-tissue sarcoma. (27148925)
2016
32
SU-G-JeP4-14: Assessment of Inter- and Intra-Fractional Motion for Extremity Soft Tissue Sarcoma Patients by Using In-House Real-Time Optical Image-Based Monitoring System. (28047555)
2016
33
PROLONGED FEVER WITHOUT OBVIOUS ETIOLOGY FINALLY DIAGNOSED AS HIGH-GRADE SOFT TISSUE SARCOMA. (27125079)
2016
34
Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005. (27082136)
2016
35
Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients. (27622032)
2016
36
Cardiac dysfunction among soft tissue sarcoma patients in Denmark. (27186077)
2016
37
The width of resection margins influences local recurrence in soft tissue sarcoma patients. (27107792)
2016
38
Time interval between surgery and start of adjuvant radiotherapy in patients with soft tissue sarcoma: A retrospective analysis of 1131 cases from the French Sarcoma Group. (27207359)
2016
39
Raf Kinase Inhibitor Protein Expression and Prognostic Value in Soft Tissue Sarcomas. (26859895)
2016
40
Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma. (27116656)
2016
41
Older Age Modifies Oncologic Outcome Following Radiotherapy in Soft-tissue Sarcoma: A Subtype-specific SEER Analysis. (27069154)
2016
42
Symptom burden in advanced Soft Tissue Sarcoma. (28042077)
2016
43
Radiation Therapy for Soft Tissue Sarcoma: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, Intraoperative Radiation Therapy, and Brachytherapy. (27591502)
2016
44
Role of isolated limb perfusion with recombinant human tumor necrosis factor I+ and melphalan in locally advanced extremity soft tissue sarcoma. (27197621)
2016
45
Early detection of local recurrence after soft tissue sarcoma resection and flap reconstruction. (27184055)
2016
46
Adipose-induced Retroperitoneal Soft Tissue Sarcoma (RSTS) Tumorigenesis: A Potential Crosstalk between Sarcoma and Fat Cells. (27621268)
2016
47
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. (27208537)
2016
48
Evaluation of minimal disseminated disease in cryopreserved ovarian tissue from bone and soft tissue sarcoma patients. (27591237)
2016
49
Initial Experience: Alleviation of Pain with Percutaneous CT-Guided Cryoablation for Recurrent Retroperitoneal Soft-Tissue Sarcoma. (27617909)
2016
50
Spontaneous cutaneous soft tissue sarcoma with differentiation into fibroblasts in a Sprague-Dawley rat. (27182117)
2016

Variations for Soft Tissue Sarcoma

About this section

Clinvar genetic disease variations for Soft Tissue Sarcoma:

5
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_000546.5(TP53): c.743G> A (p.Arg248Gln)SNVLikely pathogenic, Pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
2PIK3CANM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)SNVPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091

Expression for genes affiliated with Soft Tissue Sarcoma

About this section
Search GEO for disease gene expression data for Soft Tissue Sarcoma.

Pathways for genes affiliated with Soft Tissue Sarcoma

About this section

Pathways related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 59)
idSuper pathwaysScoreTop Affiliating Genes
19.9MDM2, TP53
29.8IFNG, PIK3CA
39.7BCL2, PIK3CA
49.6MDM2, PIK3CA, TP53
59.6IFNG, VEGFA
69.6BCL2, TNF
79.5IFNG, MDM2, TP53
89.5MDM2, TP53, VEGFA
99.4IFNG, PIK3CA, TNF
109.4IFNG, PIK3CA, TNF
119.4ABCB1, BCL2
129.4BCL2, PIK3CA, TP53
13
Show member pathways
9.4BCL2, MDM2, TP53
14
Show member pathways
9.4BCL2, MDM2, TP53
159.4EGFR, PIK3CA
16
Show member pathways
9.3BCL2, TNF, TP53
179.3IFNG, TNF, VEGFA
189.2LATS1, MDM2, MKI67, TP53
19
Show member pathways
9.2BCL2, IFNG, TNF
20
Show member pathways
9.1EGFR, PIK3CA, TP53
219.1EGFR, PIK3CA, TP53
229.1EGFR, MDM2, TP53
23
Show member pathways
9.1EGFR, MDM2, PIK3CA
24
Show member pathways
9.1EGFR, MDM2, PIK3CA
259.1BCL2, PIK3CA, TNF, TP53
26
Show member pathways
9.0BCL2, PIK3CA, TERT
279.0BCL2, TERT, TNF
289.0BCL2, IFNG, MDM2, TP53
299.0PIK3CA, TERT, TNF, TP53
308.9BCL2, MDM2, TP53, VEGFA
31
Show member pathways
8.9BCL2, IFNG, PIK3CA, TNF
32
Show member pathways
8.9BCL2, IFNG, PIK3CA, TNF
338.9EGFR, PIK3CA, VEGFA
348.9ABCB1, TERT, VEGFA
358.9BCL2, PIK3CA, TNF, VEGFA
36
Show member pathways
8.8EGFR, MDM2, PIK3CA, TP53
37
Show member pathways
8.8BCL2, MDM2, PIK3CA, TNF, TP53
388.8EGFR, PIK3CA, TNF, TP53
398.7BCL2, IFNG, MDM2, PIK3CA, TP53
40
Show member pathways
8.6BCL2, IFNG, PIK3CA, TNF, TP53
41
Show member pathways
8.6EGFR, IFNG, TNF, TP53
428.6EGFR, IFNG, TNF, TP53
438.6EGFR, MDM2, TP53, VEGFA
448.6EGFR, IFNG, TERT
458.6BCL2, EGFR, MDM2, TP53
46
Show member pathways
8.4BCL2, EGFR, IFNG, PIK3CA
47
Show member pathways
8.3EGFR, MDM2, PIK3CA, TP53, VEGFA
48
Show member pathways
8.3BCL2, EGFR, MDM2, PIK3CA, TP53
49
Show member pathways
8.3BCL2, EGFR, MDM2, PIK3CA, TP53
50
Show member pathways
8.3BCL2, EGFR, MDM2, PIK3CA, TP53

GO Terms for genes affiliated with Soft Tissue Sarcoma

About this section

Biological processes related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show all 31)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of protein export from nucleusGO:004682710.5MDM2, TP53
2negative regulation of growth of symbiont in hostGO:004413010.5IFNG, TNF
3positive regulation of calcidiol 1-monooxygenase activityGO:006055910.4IFNG, TNF
4negative regulation of anoikisGO:200081110.4BCL2, PIK3CA
5positive regulation of chemokine biosynthetic processGO:004508010.4IFNG, TNF
6positive regulation of membrane protein ectodomain proteolysisGO:005104410.4IFNG, TNF
7positive regulation of osteoclast differentiationGO:004567210.4IFNG, TNF
8positive regulation of vitamin D biosynthetic processGO:006055710.4IFNG, TNF
9regulation of mitochondrial membrane permeabilityGO:004690210.3BCL2, TP53
10positive regulation of protein complex assemblyGO:003133410.3TNF, VEGFA
11replicative senescenceGO:009039910.2TERT, TP53
12positive regulation of vascular associated smooth muscle cell migrationGO:190475410.2MDM2, TERT
13positive regulation of vascular smooth muscle cell proliferationGO:190470710.2MDM2, TERT
14positive regulation of cell adhesionGO:004578510.0IFNG, TNF, VEGFA
15humoral immune responseGO:000695910.0BCL2, IFNG, TNF
16digestive tract morphogenesisGO:00485469.9BCL2, EGFR
17positive regulation of apoptotic processGO:00430659.9IFNG, LATS1, TNF, TP53
18negative regulation of neuron apoptotic processGO:00435249.8BCL2, PIK3CA, TERT
19negative regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:20012409.7BCL2, TERT, TNF
20response to iron ionGO:00100399.7BCL2, MDM2
21negative regulation of gene expressionGO:00106299.6IFNG, MDM2, TERT, TNF
22positive regulation of nitric oxide biosynthetic processGO:00454299.6EGFR, IFNG, TNF
23positive regulation of MAP kinase activityGO:00434069.5EGFR, TNF, VEGFA
24negative regulation of transcription from RNA polymerase II promoterGO:00001229.4IFNG, MDM2, TNF, TP53, VEGFA
25positive regulation of gene expressionGO:00106289.4IFNG, MDM2, TNF, TP53, VEGFA
26cell proliferationGO:00082839.3BCL2, EGFR, MKI67, TP53
27positive regulation of peptidyl-serine phosphorylationGO:00331389.2BCL2, LATS1, PIK3CA, TNF, VEGFA
28cellular response to hypoxiaGO:00714569.1BCL2, MDM2, TERT, TP53, VEGFA
29response to drugGO:00424939.1ABCB1, BCL2, IFNG, MDM2
30positive regulation of cell proliferationGO:00082848.7BCL2, EGFR, IFNG, MDM2, VEGFA
31negative regulation of apoptotic processGO:00430668.2BCL2, EGFR, MDM2, TERT, TP53, VEGFA

Molecular functions related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protease bindingGO:000202010.2BCL2, TNF, TP53
2protein phosphatase bindingGO:00199039.5BCL2, EGFR, TP53
3ATP bindingGO:00055248.7ABCB1, EGFR, LATS1, MKI67, PIK3CA, TP53
4identical protein bindingGO:00428028.6BCL2, EGFR, MDM2, TNF, TP53, VEGFA
5ubiquitin protein ligase bindingGO:00316258.6BCL2, EGFR, MDM2, TP53
6protein bindingGO:00055155.9ABCB1, BCL2, EGFR, IFNG, LATS1, MDM2

Sources for Soft Tissue Sarcoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet